Clinical Trials
A listing of current leukemia, myelodysplastic syndrome and bone marrow cancer clinical trials available at UNC Lineberger Comprehensive Cancer Center.
Acute Myeloid Leukemia (AML)
| Study # | Study Title | PI |
|---|---|---|
| J1651 | Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients | Joshua Zeidner, MD |
| LCCC1522 | High Dose Cytarabine Followed by Pembrolizumab in Relapsed/ Refractory AML | Joshua Zeidner, MD |
| TPI-ALV-101 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Joshua Zeidner, MD |
| TPI-ALV-201 |
Alvocidib Biomarker-driven Phase 2 AML Study |
Joshua Zeidner, MD |
Acute Lymphoblastic Leukemia (ALL)
| Study # | Study Title | PI |
|---|---|---|
| A041501-CIRB |
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia |
Matthew Foster, MD |
| E1910 |
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia |
Katarzyna Jamieson, MD |
| LCCC1541-ATL |
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia |
Matthew Foster, MD |
Myelodysplastic Syndromes (MDS)
| Study # | Study Title | PI |
|---|---|---|
| H3B-8800-G000-101 | Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia | Callie Coombs, MD |
Other Bone Marrow Cancers
| Study # | Study Title | PI |
|---|---|---|
| INCB57643-101 | A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies | Callie Coombs, MD |
| CP-MGD006-01 | Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS | Matthew Foster MD |